Galderma Group AG
An Open-label Study of Poly-l-lactic Acid for Correction of Wrinkles in the décolletage Area
- Conditions
- Wrinkles in Decolletage
- Interventions
- Device: poly-l-lactic acid (Sculptra)
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 30
- Registration Number
- NCT05538728
- Locations
- 🇺🇸
Galderma Study Site, Solana Beach, California, United States
Sculptra Chart Review
- Conditions
- Non-facial Skin Aesthetic Conditions
- Interventions
- Device: Sculptra Aesthetic
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 500
- Registration Number
- NCT05463978
- Locations
- 🇺🇸
Galderma Research Site, New York, New York, United States
🇺🇸Site Coordinator, New York, New York, United States
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: OnabotulinumtoxinABiological: QM1114-DPBiological: Placebo
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 605
- Registration Number
- NCT05463965
- Locations
- 🇨🇳
Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China
🇨🇳Xiangya 3rd Hospital, Changsha, Hunan, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 192
- Registration Number
- NCT05405985
- Locations
- 🇺🇸
Galderma Investigational Site 7024, Tempe, Arizona, United States
🇺🇸Galderma Investigational Site 7023, Lincoln, Nebraska, United States
Safety and Effectiveness of Restylane® Kysse for Lip Augmentation in Chinese Subjects
- Conditions
- Lip Augmentation
- Interventions
- Device: Restylane Kysse
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT05342753
- Locations
- 🇨🇳
Galderma Research Site, Taipei, Taiwan
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
- Conditions
- Glabellar Frown Lines
- Interventions
- Biological: AlluzienceBiological: powder BoNT-A (BOTOX/Vistabel)
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 150
- Registration Number
- NCT05277337
- Locations
- 🇩🇪
Galderma Research Site 2003, Bochum, Germany
🇩🇪Galderma Research Site 2001, Düsseldorf, Germany
🇩🇪Galderma Research Site 2002, Düsseldorf, Germany
Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
- Conditions
- Midface Contour DeficienciesCheek Wrinkles
- Interventions
- Device: GP0112Device: Restylane Lyft Lidocaine
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 211
- Registration Number
- NCT05262777
- Locations
- 🇨🇦
Galderma Research Site, Montréal, Quebec, Canada
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
- Conditions
- Glabellar Frown LinesCanthal Lines
- Interventions
- Biological: QM1114-DP
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 25
- Registration Number
- NCT05148000
- Locations
- 🇺🇸
Galderma Research Site, New York, New York, United States
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
- Conditions
- Glabellar Frown Lines
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 132
- Registration Number
- NCT05146999
- Locations
- 🇺🇸
Galderma Research Site, Spring, Texas, United States
Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction
- Conditions
- Midface Contour DeficienciesCheek Wrinkles
- Interventions
- Device: Restylane Lyft LidocaineDevice: GP0112
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Registration Number
- NCT05098457
- Locations
- 🇩🇪
Galderma Research Site, Wuppertal, Germany